These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31948897)

  • 1. Screening for cognitive impairment in non-affective psychoses: A comparison between the SCIP and the MoCA.
    Belvederi Murri M; Folesani F; Costa S; Biancosino B; Colla C; Zerbinati L; Caruso R; Nanni MG; Purdon SE; Grassi L
    Schizophr Res; 2020 Apr; 218():188-194. PubMed ID: 31948897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the MoCA for cognitive impairment screening in long-term psychosis patients.
    Gil-Berrozpe GJ; Sánchez-Torres AM; García de Jalón E; Moreno-Izco L; Fañanás L; Peralta V; Cuesta MJ;
    Schizophr Res; 2020 Feb; 216():429-434. PubMed ID: 31801676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for cognitive screening in old age psychiatry: Determining cutoff scores in clinical practice. Avoiding spectrum bias caused by healthy controls.
    Dautzenberg G; Lijmer J; Beekman A
    Int J Geriatr Psychiatry; 2020 Mar; 35(3):261-269. PubMed ID: 31650623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: a comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP).
    Cuesta MJ; Pino O; Guilera G; Rojo JE; Gómez-Benito J; Purdon SE; Franco M; Martínez-Arán A; Segarra N; Tabarés-Seisdedos R; Vieta E; Bernardo M; Crespo-Facorro B; Mesa F; Rejas J
    Schizophr Res; 2011 Aug; 130(1-3):137-42. PubMed ID: 21652178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The screen for cognitive impairment in psychiatry in patients with borderline personality disorder.
    Folesani F; Belvederi Murri M; Biancosino B; Costa S; Zerbinati L; Caruso R; Nanni MG; Toffanin T; Ferrara M; Purdon SE; Grassi L
    Personal Ment Health; 2022 Nov; 16(4):279-289. PubMed ID: 35146968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia.
    Pino O; Guilera G; Rojo JE; Gómez-Benito J; Bernardo M; Crespo-Facorro B; Cuesta MJ; Franco M; Martinez-Aran A; Segarra N; Tabarés-Seisdedos R; Vieta E; Purdon SE; Díez T; Rejas J;
    Schizophr Res; 2008 Feb; 99(1-3):139-48. PubMed ID: 17959358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Criterion and convergent validity of the Montreal cognitive assessment with screening and standardized neuropsychological testing.
    Lam B; Middleton LE; Masellis M; Stuss DT; Harry RD; Kiss A; Black SE
    J Am Geriatr Soc; 2013 Dec; 61(12):2181-2185. PubMed ID: 24320735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Quick Mild Cognitive Impairment (Qmci) screen to the Montreal Cognitive Assessment (MoCA) in an Australian geriatrics clinic.
    Clarnette R; O'Caoimh R; Antony DN; Svendrovski A; Molloy DW
    Int J Geriatr Psychiatry; 2017 Jun; 32(6):643-649. PubMed ID: 27427212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of the Montreal Cognitive Assessment (MoCA) screening tool to evaluate cognitive deficits in Lebanese in-patients with schizophrenia.
    Haddad C; Salameh P; Sacre H; Clément JP; Calvet B
    Asian J Psychiatr; 2022 Apr; 70():103029. PubMed ID: 35189473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Utility of the TYM and RBANS in a One-Stop Memory Clinic in Singapore: A Pilot Study.
    Dong Y; Ling MTY; Ng KET; Wang A; Wan EYS; Merchant RA; Venketasubramanian N; Chen CL; Mahendran R; Collinson SL
    J Geriatr Psychiatry Neurol; 2019 Mar; 32(2):68-73. PubMed ID: 30630388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of the Montreal Cognitive Assessment (MoCA) in patients suspected of cognitive impairment in old age psychiatry. Using the MoCA for triaging to a memory clinic.
    Dautzenberg G; Lijmer J; Beekman A
    Cogn Neuropsychiatry; 2021 Jan; 26(1):1-17. PubMed ID: 33272076
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening for cognitive impairment in systemic lupus erythematosus: Application of the Montreal Cognitive Assessment (MoCA) in a Greek patient sample.
    Papastefanakis E; Dimitraki G; Ktistaki G; Fanouriakis A; Karamaouna P; Bardos A; Kallitsakis I; Adamichou C; Gergianaki I; Repa A; Bertsias G; Sidiropoulos P; Karademas E; Simos P
    Lupus; 2021 Dec; 30(14):2237-2247. PubMed ID: 34861804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using the cognitive assessment interview to screen cognitive impairment in psychosis.
    Sánchez-Torres AM; Elosúa MR; Lorente-Omeñaca R; Moreno-Izco L; Peralta V; Ventura J; Cuesta MJ
    Eur Arch Psychiatry Clin Neurosci; 2016 Oct; 266(7):629-37. PubMed ID: 27272500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and validation of a brief scale for cognitive evaluation in people with a diagnosis of schizophrenia (BCog-S).
    Sánchez-Martínez V; Sales-Orts R
    J Psychiatr Ment Health Nurs; 2020 Oct; 27(5):543-552. PubMed ID: 31976597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for Mild Cognitive Impairment: Comparison of "MCI Specific" Screening Instruments.
    O'Caoimh R; Timmons S; Molloy DW
    J Alzheimers Dis; 2016; 51(2):619-29. PubMed ID: 26890758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for cognitive impairment in schizophrenia: Psychometric properties of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G).
    Sachs G; Lasser I; Purdon SE; Erfurth A
    Schizophr Res Cogn; 2021 Sep; 25():100197. PubMed ID: 34026572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Italian Validation of the Screen for Cognitive Impairment in Psychiatry.
    Belvederi Murri M; Folesani F; Costa S; Morelli AC; Scillitani V; Guaiana G; Biancosino B; Caruso R; Nanni MG; Zerbinati L; Purdon SE; Grassi L
    Community Ment Health J; 2020 Nov; 56(8):1411-1418. PubMed ID: 32076904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
    Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
    Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The screen for cognitive impairment in psychiatry (SCIP) as a routinely applied screening tool: pathology of acute psychiatric inpatients and cluster analysis.
    Schmid P; Czekaj A; Frick J; Steinert T; Purdon SE; Uhlmann C
    BMC Psychiatry; 2021 Oct; 21(1):494. PubMed ID: 34627191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning.
    Fazeli PL; Casaletto KB; Paolillo E; Moore RC; Moore DJ; The Hnrp Group
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):842-853. PubMed ID: 28122474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.